Diagnostic efficacy of serum microRNA-375 and microRNA-760 combined with liver enhancement computed tomography in hepatocellular carcinoma

LIU Mengwen; LIU Qunli; YANG Jie

doi:10.7619/jcmp.20233549

Journal of Clinical Medicine in Practice > 2024 > 28(23): 47-51. > DOI: 10.7619/jcmp.20233549

LIU Mengwen, LIU Qunli, YANG Jie. Diagnostic efficacy of serum microRNA-375 and microRNA-760 combined with liver enhancement computed tomography in hepatocellular carcinoma[J]. Journal of Clinical Medicine in Practice, 2024, 28(23): 47-51. DOI: 10.7619/jcmp.20233549

Citation:

PDF (878 KB)

Diagnostic efficacy of serum microRNA-375 and microRNA-760 combined with liver enhancement computed tomography in hepatocellular carcinoma

Department of Medical Imaging, the First Affiliated Hospital of Henan University, Kaifeng, Henan, 475002

More Information

Received Date: November 06, 2023
Revised Date: January 02, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the diagnostic efficacy of serum microRNA-375 (miR-375) and microRNA-760 (miR-760) combined liver enhancement computed tomography(CT) in hepatocellular carcinoma (HCC).
Methods
A total of 144 patients with HCC were included in cancer group, and another 144 patients with benign liver tumors in the same period were included in benign group. The expression levels of serum miR-375 and miR-760 were measured in both groups. Receiver operating characteristic (ROC) curves were plotted to analyze the diagnostic value of serum miR-375 and miR-760 expression levels combined with liver enhancement CT in HCC. The Kappa test was used to analyze the consistency of lonely detection of serum miR-375, miR-760 levels and liver enhancement CT, and their combined diagnosis for HCC with the gold standard pathological results.
Results
The expression levels of serum miR-375 and miR-760 in the cancer group were significantly lower than those in the benign group (P<0.05). The expression levels of serum miR-375 and miR-760 in patients with HCC were correlated with the number of tumor, tumor diameter, TNM stage, distant organ metastasis, degree of differentiation, portal vein tumor thrombus, and hepatitis B surface antigen (P<0.05). The ROC curve analysis showed that the area under the curve (AUC) of combined diagnosis of HCC using serum miR-375, miR-760, and liver enhancement CT was significantly greater than the AUC of individual diagnosis of the three methods (P<0.05), and there was a high consistency with pathological results (Kappa=0.826).
Conclusion
The expression levels of serum miR-375 and miR-760 in patients with HCC are lower than those in patients with benign liver tumors. The combined use of serum miR-375 and miR-760 levels and liver enhancement CT technology can significantly improve the diagnostic efficacy of HCC.
- hepatocellular carcinoma,
- microRNA-375,
- microRNA-760,
- liver enhancement computed tomography,
- diagnostic efficacy

FullText(HTML)

References (24)

References

[1]	VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362. doi: 10.1016/S0140-6736(22)01200-4
[2]	王丽菲, 罗龙龙, 郑英, 等. 巨噬细胞移动抑制因子在肝细胞癌中的研究进展[J]. 实用临床医药杂志, 2023, 27(14): 126-130. doi: 10.7619/jcmp.20231220
[3]	彭敏. 动态增强CT诊断肝细胞癌的影像表现及应用价值[J]. 现代诊断与治疗, 2021, 32(20): 3311-3312.
[4]	刘向东, 闫松果, 孙世松. 动态增强CT扫描与MRI对肝细胞癌的诊断价值及影像学特征分析[J]. 实用癌症杂志, 2023, 38(1): 89-91. doi: 10.3969/j.issn.1001-5930.2023.01.025
[5]	WEI J H, LU Y R, WANG R Q, et al. MicroRNA-375: potential cancer suppressor and therapeutic drug[J]. Biosci Rep, 2021, 41(9): BSR20211494. doi: 10.1042/BSR20211494
[6]	JOKOVIC S M, DOBRIJEVIC Z, KOTARAC N, et al. MiR-375 and miR-21 as potential biomarkers of prostate cancer: comparison of matching samples of plasma and exosomes[J]. Genes, 2022, 13(12): 2320. doi: 10.3390/genes13122320
[7]	MANVATI M K S, KHAN J, VERMA N, et al. Association of miR-760 with cancer: an overview[J]. Gene, 2020, 747: 144648. doi: 10.1016/j.gene.2020.144648
[8]	HUANG X J, LAI S Q, QU F L, et al. CCL18 promotes breast cancer progression by exosomal miR-760 activation of ARF6/Src/PI3K/Akt pathway[J]. Mol Ther Oncolytics, 2022, 25: 1-15. doi: 10.1016/j.omto.2022.03.004
[9]	黄伟康, 文戈, 吴水天, 等. CT扫描联合血清AFP-L3、CEA在诊断肝细胞癌中的应用价值分析[J]. 医学影像学杂志, 2021, 31(5): 810-813.
[10]	王莉琳, 张永宏, 陈新月. 2010年美国肝病年会(AASLD)肝细胞癌诊疗指南[J]. 北京医学, 2011, 33(3): 236-251.
[11]	郑可国, 许达生, 李子平. 肝细胞癌临床CT诊断[M]. 广州: 广东世界图书出版公司, 2003: 22-67.
[12]	CALDERARO J, SERAPHIN T P, LUEDDE T, et al. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma[J]. J Hepatol, 2022, 76(6): 1348-1361. doi: 10.1016/j.jhep.2022.01.014
[13]	SUGAWARA Y, HIBI T. Surgical treatment of hepatocellular carcinoma[J]. Biosci Trends, 2021, 15(3): 138-141. doi: 10.5582/bst.2021.01094
[14]	LLOVET J M, BAERE T D, KULIK L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5): 293-313. doi: 10.1038/s41575-020-00395-0
[15]	吴建峰, 李林静, 方春, 等. 个体化碘对比剂注射速率方案在肝脏增强CT中提高增强质量一致性的价值[J]. 中国医师杂志, 2022, 24(3): 456-458. doi: 10.3760/cma.j.cn431274-20210518-00556
[16]	LIU C F, LI J, WANG W, et al. MiR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression[J]. Cell Cycle, 2020, 19(10): 1077-1088. doi: 10.1080/15384101.2020.1739808
[17]	LIU Y, WANG Q Y, WEN J, et al. MiR-375: a novel multifunctional regulator[J]. Life Sci, 2021, 275: 119323. doi: 10.1016/j.lfs.2021.119323
[18]	NI H W, QIN H, SUN C, et al. MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis[J]. Stem Cell Res Ther, 2021, 12(1): 325. doi: 10.1186/s13287-021-02394-7
[19]	WANG C, LUO J, CHEN Z H, et al. MiR-375 impairs the invasive capabilities of hepatoma cells by targeting HIF1α under hypoxia[J]. Dig Dis Sci, 2021, 66(2): 493-502. doi: 10.1007/s10620-020-06202-9
[20]	XU R, YIN S W, ZHENG M, et al. Circular RNA circZFR promotes hepatocellular carcinoma progression by regulating miR-375/HMGA2 axis[J]. Dig Dis Sci, 2021, 66(12): 4361-4373. doi: 10.1007/s10620-020-06805-2
[21]	WU X D, CHEN H, LIU N, et al. Curcumin suppresses lung cancer progression via circRUNX1 mediated miR-760/RAB3D axis[J]. Thorac Cancer, 2023, 14(5): 506-516. doi: 10.1111/1759-7714.14773
[22]	WANG Q H, WANG G, XU X D, et al. MiR-760 mediated the proliferation and metastasis of hepatocellular carcinoma cells by regulating HMGA2[J]. Pathol Res Pract, 2021, 222: 153420. doi: 10.1016/j.prp.2021.153420
[23]	YIN L N, SUN T T, LIU R B. NACC-1 regulates hepatocellular carcinoma cell malignancy and is targeted by miR-760[J]. Acta Biochim Biophys Sin, 2020, 52(3): 302-309. doi: 10.1093/abbs/gmz167
[24]	LI J F, QIN Y Y, WANG W J, et al. Peiminine inhibits the progression of colorectal cancer through up-regulating miR-760 via declining the expression of long noncoding RNA LINC00659[J]. Anticancer Drugs, 2021, 32(2): 148-156. doi: 10.1097/CAD.0000000000000981

Cited By

Get Citation

PDF

XML

Article views (80) PDF downloads (11)

Turn off MathJax

Article Contents

Abstract

References

Diagnostic efficacy of serum microRNA-375 and microRNA-760 combined with liver enhancement computed tomography in hepatocellular carcinoma

Abstract

References

Catalog

Export File

Citation

Format

Content